CLRB ▲ +0.5% - Cellectar Biosciences, Inc.
$CLRB CLRBW CLRBZ - Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
29-SEP-2026 07:30 AM ET
Share this post
More filings for $CLRB
CLRB ▲ +6.7% - Cellectar Biosciences, Inc.Oct 15, 2026CLRB - Cellectar Biosciences, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026CLRB - Cellectar Biosciences, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026CLRB - Cellectar Biosciences, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026CLRB - Cellectar Biosciences, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026CLRB SEC Filing Update (04-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 4, 2026
View full $CLRB filing history →💬 Comments
Loading comments…
Leave a comment